Recent research into retatritide peptide highlight significant outlook for managing obesity and type disease. The compound, a dual agonist of GLP-1 receptor and GIP receptor, seems to offer enhanced weight reduction and glucose regulation in contrast to existing medications. Ongoing patient studi